<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">26423</article-id><article-id pub-id-type="doi">10.7554/eLife.26423</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-82914"><name><surname>Marçais</surname><given-names>Antoine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82915"><name><surname>Marotel</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82916"><name><surname>Degouve</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82917"><name><surname>Koenig</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82918"><name><surname>Fauteux-Daniel</surname><given-names>Sébastien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82919"><name><surname>Drouillard</surname><given-names>Annabelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-96235"><name><surname>Schlums</surname><given-names>Heinrich</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82920"><name><surname>Viel</surname><given-names>Sébastien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82921"><name><surname>Besson</surname><given-names>Laurie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82922"><name><surname>Allatif</surname><given-names>Omran</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82923"><name><surname>Bléry</surname><given-names>Mathieu</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-8581"><name><surname>Vivier</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-82924"><name><surname>Bryceson</surname><given-names>Yenan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82925"><name><surname>Thaunat</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-82554"><name><surname>Walzer</surname><given-names>Thierry</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0857-8179</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>International Center for Infectiology Research (CIRI)</institution>, <addr-line><named-content content-type="city">Lyon</named-content></addr-line>, <country>France</country></aff><aff id="aff2"><institution content-type="dept">Centre for Hematology and Regenerative Medicine, Department of Medicine</institution>, <institution>Karolinska Institutet, Karolinska University Hospital Huddinge</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff3"><institution>Innate Pharma</institution>, <addr-line><named-content content-type="city">Marseille</named-content></addr-line>, <country>France</country></aff><aff id="aff4"><institution content-type="dept">Centre d'Immunologie de Marseille-Luminy</institution>, <institution>Aix Marseille Université</institution>, <addr-line><named-content content-type="city">Marseille</named-content></addr-line>, <country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-8269"><name><surname>Yokoyama</surname><given-names>Wayne M</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Washington University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>antoine.marcais@inserm.fr</email> (AM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>thierry.walzer@inserm.fr</email> (TW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>09</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e26423</elocation-id><history><date date-type="received"><day>28</day><month>02</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Marçais et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Marçais et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-26423-v1.pdf"/><abstract><p>NK cell education is the process through which chronic engagement of inhibitory NK cell receptors by self MHC-I molecules preserves cellular responsiveness. The molecular mechanisms responsible for NK cell education remain unclear. Here, we show that mouse NK cell education is associated with a higher basal activity of the mTOR/Akt pathway, commensurate to the number of educating receptors. This higher activity was dependent on the SHP-1 phosphatase and essential for the improved responsiveness of reactive NK cells. Upon stimulation, the mTOR/Akt pathway amplified signaling through activating NK cell receptors by enhancing calcium flux and LFA-1 integrin activation. Pharmacological inhibition of mTOR resulted in a proportional decrease in NK cell reactivity. Reciprocally, acute cytokine stimulation restored reactivity of hyporesponsive NK cells through mTOR activation. These results demonstrate that mTOR acts as a molecular rheostat of NK cell reactivity controlled by educating receptors and uncover how cytokine stimulation overcomes NK cell education.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-16-CE15-0005-01 Bank</award-id><principal-award-recipient><name><surname>Marçais</surname><given-names>Antoine</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>281025 Dironaki</award-id><principal-award-recipient><name><surname>Walzer</surname><given-names>Thierry</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Mathieu Bléry, MB is employee of Innate-Pharma.</p></fn><fn fn-type="conflict" id="conf3"><p>Eric Vivier, EV is shareholder of Innate-Pharma.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was carried out in accordance with the French recommendations in the Guide for the ethical evaluation of experiments using laboratory animals and the European guidelines 86/609/CEE. All experimental studies were approved by the bioethic local committee CECCAPP (Permit number: CECCAPP_ENS_2014_018).</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-26423-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>